YAZICI, A. Et Al. 2022. A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry. Scientific reports , vol.12, no.1 , 21972.

YAZICI, A., Özdemir Işık, Ö., DALKILIÇ, H. E., Koca, S. S., PEHLİVAN, Y., Şenel, S., ... İNANÇ, G. N.(2022). A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry. Scientific reports , vol.12, no.1, 21972.

YAZICI, AYTEN Et Al. "A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry," Scientific reports , vol.12, no.1, 21972, 2022

YAZICI, AYTEN Et Al. "A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry." Scientific reports , vol.12, no.1, pp.21972, 2022

YAZICI, A. Et Al. (2022) . "A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry." Scientific reports , vol.12, no.1, p.21972.

@article{article, author={AYTEN YAZICI Et Al. }, title={A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry}, journal={Scientific reports}, year=2022, pages={21972} }